Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $24
Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $24
古根海姆維持對Centessa Pharmaceuticals的買入評級，將目標股價上調至24美元
Guggenheim analyst Debjit Chattopadhyay maintains Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy and raises the price target from $20 to $24.
古根海姆分析師德布吉特·查託帕迪亞維持Centessa Pharmicals（納斯達克股票代碼：CNTA）的買入並將目標股價從20美元上調至24美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。